515MO Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (Pts) with advanced EGFR-mutated (Mut), c-Met overexpressing (OE) non-small cell lung cancer (NSCLC): Final efficacy and safety updates

Clinical evidence supports c-Met as a target in pts with advanced EGFR-mut NSCLC after progression on osimertinib (O; third-generation EGFR-TKI). Here we report the final results of the Teliso-V (T; first-in-class c-Met–targeting ADC) + O combination arm of the phase 1b study (NCT02099058) in pts with advanced/metastatic EGFR-mut, c-Met OE NSCLC with progression on prior O.